<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">35776734</article-id><article-id pub-id-type="pmc">9249242</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0270506</article-id><article-id pub-id-type="publisher-id">PONE-D-21-37015</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Developmental Psychology</subject><subj-group><subject>Pervasive Developmental Disorders</subject><subj-group><subject>Autism Spectrum Disorder</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Developmental Psychology</subject><subj-group><subject>Pervasive Developmental Disorders</subject><subj-group><subject>Autism Spectrum Disorder</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Post-Translational Modification</subject><subj-group><subject>Glycation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Computational Biology</subject><subj-group><subject>Genome Complexity</subject><subj-group><subject>Copy Number Variation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Genome Complexity</subject><subj-group><subject>Copy Number Variation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Mental Health and Psychiatry</subject><subj-group><subject>Schizophrenia</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Medical Risk Factors</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Bioenergetics</subject><subj-group><subject>Energy-Producing Organelles</subject><subj-group><subject>Mitochondria</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Structures and Organelles</subject><subj-group><subject>Energy-Producing Organelles</subject><subj-group><subject>Mitochondria</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Developmental Psychology</subject><subj-group><subject>Pervasive Developmental Disorders</subject><subj-group><subject>Autism Spectrum Disorder</subject><subj-group><subject>Autism</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Developmental Psychology</subject><subj-group><subject>Pervasive Developmental Disorders</subject><subj-group><subject>Autism Spectrum Disorder</subject><subj-group><subject>Autism</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Neurodevelopmental Disorders</subject><subj-group><subject>Autism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Developmental Neuroscience</subject><subj-group><subject>Neurodevelopmental Disorders</subject><subj-group><subject>Autism</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Neurodevelopmental Disorders</subject><subj-group><subject>Autism</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Oxidative Stress</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Exonic deletions in <italic toggle="yes">IMMP2L</italic> in schizophrenia with enhanced glycation stress subtype</article-title><alt-title alt-title-type="running-head">CNVs in schizophrenia with enhanced glycation stress</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5271-5927</contrib-id><name><surname>Yoshikawa</surname><given-names>Akane</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="currentaff001" ref-type="author-notes">
<sup>&#x000a4;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kushima</surname><given-names>Itaru</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Miyashita</surname><given-names>Mitsuhiro</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Suzuki</surname><given-names>Kazuhiro</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Iino</surname><given-names>Kyoka</given-names></name><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8593-3269</contrib-id><name><surname>Toriumi</surname><given-names>Kazuya</given-names></name><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0597-2514</contrib-id><name><surname>Horiuchi</surname><given-names>Yasue</given-names></name><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kawaji</surname><given-names>Hideya</given-names></name><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ozaki</surname><given-names>Norio</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Itokawa</surname><given-names>Masanari</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3400-9815</contrib-id><name><surname>Arai</surname><given-names>Makoto</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo, Japan</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Setagaya, Tokyo, Japan</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Medical Genomics Center, Nagoya University Hospital, Nagoya, Aichi, Japan</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of Psychiatry, Takatsuki Clinic, Akishima, Tokyo, Japan</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Research Center for Genome &#x00026; Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo, Japan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Kazuya</surname><given-names>Iwamoto</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Kumamoto University Faculty of Life Sciences School of Medicine: Kumamoto Daigaku Daigakuin Seimei Kagaku Kenkyubu Igakubu, JAPAN</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="current-aff" id="currentaff001"><label>&#x000a4;</label><p>Current address: Department of Psychiatry &#x00026; Behavioral Science, Juntendo University Graduate School of Medicine, Bunkyo, Tokyo, Japan</p></fn><corresp id="cor001">* E-mail: <email>arai-mk@igakuken.or.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>1</day><month>7</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>17</volume><issue>7</issue><elocation-id>e0270506</elocation-id><history><date date-type="received"><day>22</day><month>11</month><year>2021</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 Yoshikawa et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Yoshikawa et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0270506.pdf"/><abstract><p>We previously identified a subtype of schizophrenia (SCZ) characterized by increased plasma pentosidine, a marker of glycation and oxidative stress (PEN-SCZ). However, the genetic factors associated with PEN-SCZ have not been fully clarified. We performed a genome-wide copy number variation (CNV) analysis to identify CNVs associated with PEN-SCZ to provide an insight into the novel therapeutic targets for PEN-SCZ. Plasma pentosidine was measured by high-performance liquid chromatography in 185 patients with SCZ harboring rare CNVs detected by array comparative genomic hybridization. In three patients with PEN-SCZ showing additional autistic features, we detected a novel deletion at 7q31.1 within exons 2 and 3 of <italic toggle="yes">IMMP2L</italic>, which encodes the inner mitochondrial membrane peptidase subunit 2. The deletion was neither observed in non-PEN-SCZ nor in public database of control subjects. <italic toggle="yes">IMMP2L</italic> is one of the SCZ risk loci genes identified in a previous SCZ genome-wide association study, and its trans-populational association was recently described. Interestingly, deletions in <italic toggle="yes">IMMP2L</italic> have been previously linked with autism spectrum disorder. Disrupted IMMP2L function has been shown to cause glycation/oxidative stress in neuronal cells in an age-dependent manner. To our knowledge, this is the first genome-wide CNV study to suggest the involvement of <italic toggle="yes">IMMP2L</italic> exons 2 and 3 in the etiology of PEN-SCZ. The combination of genomic information with plasma pentosidine levels may contribute to the classification of biological SCZ subtypes that show additional autistic features. Modifying <italic toggle="yes">IMMP2L</italic> functions may be useful for treating PEN-SCZ if the underlying biological mechanism can be clarified in further studies.</p></abstract><funding-group><award-group id="award001"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap>
</funding-source><award-id>17H05090, 15K19720</award-id><principal-award-recipient>
<name><surname>Kushima</surname><given-names>Itaru</given-names></name>
</principal-award-recipient></award-group><award-group id="award002"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap>
</funding-source><award-id>18K07579</award-id><principal-award-recipient>
<name><surname>Miyashita</surname><given-names>Mitsuhiro</given-names></name>
</principal-award-recipient></award-group><award-group id="award003"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap>
</funding-source><award-id>16H05380, 17H05930, 19H04887, 20H03608</award-id><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3400-9815</contrib-id>
<name><surname>Arai</surname><given-names>Makoto</given-names></name>
</principal-award-recipient></award-group><award-group id="award004"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap>
</funding-source><award-id>19K17075</award-id><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5271-5927</contrib-id>
<name><surname>Yoshikawa</surname><given-names>Akane</given-names></name>
</principal-award-recipient></award-group><award-group id="award005"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap>
</funding-source><award-id>JP20km0405216, JP20ek0109411, JP20dm0107160</award-id><principal-award-recipient>
<name><surname>Kushima</surname><given-names>Itaru</given-names></name>
</principal-award-recipient></award-group><award-group id="award006"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap>
</funding-source><award-id>JP20ak0101113, JP20ak0101126, JP20dk0307075, JP20dm0207075, JP20dm0107087</award-id><principal-award-recipient>
<name><surname>Ozaki</surname><given-names>Norio Ozaki</given-names></name>
</principal-award-recipient></award-group><award-group id="award007"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap>
</funding-source><award-id>JP20dm0107088</award-id><principal-award-recipient>
<name><surname>Itokawa</surname><given-names>Masanari</given-names></name>
</principal-award-recipient></award-group><award-group id="award008"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100008732</institution-id><institution>Uehara Memorial Foundation</institution></institution-wrap>
</funding-source><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3400-9815</contrib-id>
<name><surname>Arai</surname><given-names>Makoto</given-names></name>
</principal-award-recipient></award-group><award-group id="award009"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100008667</institution-id><institution>SENSHIN Medical Research Foundation</institution></institution-wrap>
</funding-source><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3400-9815</contrib-id>
<name><surname>Arai</surname><given-names>Makoto</given-names></name>
</principal-award-recipient></award-group><award-group id="award010"><funding-source>
<institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100008608</institution-id><institution>Sumitomo Foundation</institution></institution-wrap>
</funding-source><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3400-9815</contrib-id>
<name><surname>Arai</surname><given-names>Makoto</given-names></name>
</principal-award-recipient></award-group><funding-statement>This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI grant (18K07579 to MM; 16H05380, 17H05930, 19H04887, 20H03608 to MA; 19K17075 to AY; 17H05090 and 15K19720 to IK); the Japan Agency for Medical Research and Development (AMED) grant (JP20km0405216, JP20ek0109411, JP20dm0107160 to IK; JP20ak0101113, JP20ak0101126, JP20dk0307075, JP20dm0207075, and JP20dm0107087 to NO; JP20dm0107088 to MI; Uehara Memorial Foundation to MA; SENSHIN Medical Research Foundation to MA; Sumitomo Foundation to MA. The JSPS, AMED, Uehara Foundation, SENSHIN Medical Research Foundation, and Sumitomo Foundation had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="2"/><page-count count="12"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its <xref rid="sec019" ref-type="sec">Supporting Information</xref> files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its <xref rid="sec019" ref-type="sec">Supporting Information</xref> files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Schizophrenia (SCZ) is a devastating psychiatric disorder with a typical onset time during adolescence or early adulthood and requires lifelong antipsychotic treatment after diagnosis. Despite intensive research efforts, treatments for SCZ remain limited to dopamine receptor D2 and 5-hydroxytryptamine receptor 2A antagonists. Novel therapeutic targets with proven efficacy have not been developed for decades.</p><p>Considering the clinical heterogeneity of SCZ [<xref rid="pone.0270506.ref001" ref-type="bibr">1</xref>], one of the most promising strategies for identifying novel therapeutic targets to develop personalized medicine is determining a specific treatment for each SCZ subtype defined by biological profiling, such as metabolome or transcriptome analysis [<xref rid="pone.0270506.ref002" ref-type="bibr">2</xref>]. We previously identified a subpopulation of SCZ characterized by high plasma pentosidine (PEN-SCZ) [<xref rid="pone.0270506.ref003" ref-type="bibr">3</xref>]. Pentosidine, an advanced glycation end product, is a biological marker of glycation and oxidative stress [<xref rid="pone.0270506.ref004" ref-type="bibr">4</xref>]. Based on these findings, we conducted a 24-week, open-label design clinical trial of pyridoxal in patients with SCZ, partially confirming its efficacy (UMIN000006398) [<xref rid="pone.0270506.ref005" ref-type="bibr">5</xref>]. Of the 10 participants, two patients showed marked improvements in psychotic symptoms, and one patient with a <italic toggle="yes">GLO1</italic> frameshift mutation showed considerable improvement accompanied by reduced plasma pentosidine levels. Hence, we sought to identify novel therapeutic target for PEN-SCZ by clarifying the causative factors through investigating genetic factors that confer the pathophysiology of PEN-SCZ.</p><p>The etiology of SCZ has a profound genetic component [<xref rid="pone.0270506.ref006" ref-type="bibr">6</xref>], with the heritability of this disease reported as 60&#x02013;80% [<xref rid="pone.0270506.ref007" ref-type="bibr">7</xref>]. Considerable progress has been made in determining the genetic architecture of SCZ. Accumulated evidence suggests that both common and rare variants are involved in the SCZ etiology [<xref rid="pone.0270506.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pone.0270506.ref012" ref-type="bibr">12</xref>]. The Psychiatric Genomic Consortium (PGC) performed a large genome-wide association study of SCZ, in which 108 risk loci, located at genes related to synaptic networks, the immune system, and mitochondrial metabolism were found to be associated with SCZ [<xref rid="pone.0270506.ref009" ref-type="bibr">9</xref>]. Recently, Ikeda et al. confirmed these findings in a trans-populational manner in European, East Asian, and Japanese populations [<xref rid="pone.0270506.ref013" ref-type="bibr">13</xref>].</p><p>An elevated burden of rare copy number variants (CNVs) among patients with SCZ has also been well-established [<xref rid="pone.0270506.ref014" ref-type="bibr">14</xref>, <xref rid="pone.0270506.ref015" ref-type="bibr">15</xref>]. Although common single-nucleotide polymorphisms have small individual effects (odds ratio (OR) &#x0003c;1.2) [<xref rid="pone.0270506.ref009" ref-type="bibr">9</xref>], several rare CNVs have been shown to have a much stronger impact on risk (OR &#x0003c;67.7) [<xref rid="pone.0270506.ref016" ref-type="bibr">16</xref>]. The PGC CNV Analysis Group successfully overcame the limited statistical power of small sample sizes and detected six novel loci, including Xq28, 7q11.21, and 8q22.2, in the largest genome-wide CNV study (N = 41,321) [<xref rid="pone.0270506.ref016" ref-type="bibr">16</xref>]. In an Asian population, Kushima et al. confirmed the increased burden of rare (&#x02264;1%) exonic CNVs using the largest sample size of the Japanese population (2,458 SCZ cases and 2,095 controls) [<xref rid="pone.0270506.ref017" ref-type="bibr">17</xref>].</p><p>In this study, we investigated rare (&#x02264;1%) CNVs associated with PEN-SCZ by assessing genome-wide CNV data [<xref rid="pone.0270506.ref017" ref-type="bibr">17</xref>] and measuring plasma pentosidine between a PEN-SCZ group and non-PEN-SCZ group.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Participants</title><p>For both genetic and biochemical analyses, 185 unrelated, ethnically Japanese patients with SCZ and identified to harbor rare (&#x02264;1%) CNVs in the previous study [<xref rid="pone.0270506.ref017" ref-type="bibr">17</xref>] were assessed in this study. All patients were recruited from the Department of Neuropsychiatry, Tokyo Metropolitan Matsuzawa Hospital, Takatsuki Hospital, Takatsuki Clinic, and RIKEN Brain Science Institute located near Tokyo. Patients were diagnosed based on the DSM-IV (American Psychiatric Association) criteria for SCZ or schizoaffective disorder by the consensus of at least two experienced psychiatrists. Patients with a history of drug addiction or alcohol abuse/dependence were excluded from the study. Patients with diabetes mellitus or chronic renal disease as a comorbidity with SCZ were also excluded from the study, as these diseases may affect plasma pentosidine levels. This study was approved by the research ethics committee of the participating institutes, and written informed consent was obtained from all subjects prior to obtaining their medical records. The present study was performed in accordance with the Declaration of Helsinki. The demographics are presented in <xref rid="pone.0270506.t001" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="pone.0270506.t001"><object-id pub-id-type="doi">10.1371/journal.pone.0270506.t001</object-id><label>Table 1</label><caption><title>Demographics and summary of CNVs in patients with schizophrenia with and without accumulation of plasma pentosidine.</title></caption><alternatives><graphic xlink:href="pone.0270506.t001" id="pone.0270506.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1">Group</th><th align="justify" rowspan="1" colspan="1">PEN-SCZ<xref rid="t001fn001" ref-type="table-fn"><sup>a</sup></xref></th><th align="left" rowspan="1" colspan="1">Non-PEN-SCZ<xref rid="t001fn002" ref-type="table-fn"><sup>b</sup></xref></th><th align="justify" rowspan="2" colspan="1">p-value</th></tr><tr><th align="justify" rowspan="1" colspan="1">Pentosidine</th><th align="justify" rowspan="1" colspan="1">High</th><th align="justify" rowspan="1" colspan="1">Normal</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Number of patients</bold>
</td><td align="left" rowspan="1" colspan="1">94</td><td align="left" rowspan="1" colspan="1">91</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age (mean &#x000b1; S.D.</bold>
<xref rid="t001fn003" ref-type="table-fn">
<sup>
<bold>c</bold>
</sup>
</xref>
<bold>)</bold>
</td><td align="left" rowspan="1" colspan="1">52.0 &#x000b1; 11.2</td><td align="left" rowspan="1" colspan="1">47.0 &#x000b1; 14.1</td><td align="left" rowspan="1" colspan="1">p &#x0003c; 0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Sex (male/female)</bold>
</td><td align="left" rowspan="1" colspan="1">50/44</td><td align="left" rowspan="1" colspan="1">46/45</td><td align="left" rowspan="1" colspan="1">p = 0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age of onset (mean &#x000b1; S.D.</bold>
<xref rid="t001fn003" ref-type="table-fn">
<sup>
<bold>c</bold>
</sup>
</xref>
<bold>)</bold>
</td><td align="left" rowspan="1" colspan="1">25.7 &#x000b1; 9.4</td><td align="left" rowspan="1" colspan="1">25.24 &#x000b1; 8.4</td><td align="left" rowspan="1" colspan="1">p = 0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Average chlorpromazine equivalent doses</bold>
</td><td align="left" rowspan="1" colspan="1">1147.58 &#x000b1; 864.02</td><td align="left" rowspan="1" colspan="1">716.43 &#x000b1; 607.65</td><td align="left" rowspan="1" colspan="1">p &#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Plasma Pentosidine level (mean &#x000b1; S.D.</bold>
<xref rid="t001fn003" ref-type="table-fn">
<sup>
<bold>c</bold>
</sup>
</xref>
<bold>) (ng/mL</bold>
<xref rid="t001fn004" ref-type="table-fn">
<sup>
<bold>d</bold>
</sup>
</xref>
<bold>)</bold>
</td><td align="left" rowspan="1" colspan="1">128.1 &#x000b1; 126.0</td><td align="left" rowspan="1" colspan="1">39.8 &#x000b1; 9.3</td><td align="left" rowspan="1" colspan="1">p &#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Average total CNV size (Mbp)</bold>
</td><td align="left" rowspan="1" colspan="1">3.6 &#x000b1; 21.9</td><td align="left" rowspan="1" colspan="1">0.4 &#x000b1; 0.5</td><td align="left" rowspan="1" colspan="1">p = 0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Average total number of genes within CNVs</bold>
</td><td align="left" rowspan="1" colspan="1">92.2 &#x000b1; 254.2</td><td align="left" rowspan="1" colspan="1">4.5 &#x000b1; 7.6</td><td align="left" rowspan="1" colspan="1">p = 0.08</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><sup>a</sup>Schizophrenia with accumulation of plasma pentosidine.</p></fn><fn id="t001fn002"><p><sup>b</sup>Schizophrenia without accumulation of plasma pentosidine.</p></fn><fn id="t001fn003"><p><sup>c</sup>Standard deviation.</p></fn><fn id="t001fn004"><p><sup>d</sup>Cut off value; 55.2.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec004"><title>CNV analysis</title><p>CNV calling was performed as described previously [<xref rid="pone.0270506.ref017" ref-type="bibr">17</xref>]. Briefly, NimbleGen 720K Whole-Genome Tiling arrays (probe spacing 2.5&#x02009;kb; Roche NimbleGen, Madison, WI, USA) were used for genome-wide CNV screening. CNV calls were made using Nexus Copy Number software v. 7.5 (BioDiscovery, El Segundo, CA, USA) with a hidden Markov model-based approach. All genomic locations are listed in the National Center for Biotechnology Information build 36/UCSC hg18 coordinates, and Lift Genome Annotations: <ext-link xlink:href="https://genome.ucsc.edu/cgi-bin/hgLiftOver" ext-link-type="uri">https://genome.ucsc.edu/cgi-bin/hgLiftOver</ext-link> was used to convert the genomic location from March 2006 (NCBI36/hg18) to December 2013 (GRCh38/hg38). All analyses were conducted based on gene annotation from GENCODE version 21 (<ext-link xlink:href="http://www.gencodegenes.org/releases/21.html" ext-link-type="uri">http://www.gencodegenes.org/releases/21.html</ext-link>) [<xref rid="pone.0270506.ref017" ref-type="bibr">17</xref>]. Randomly selected CNVs were validated using quantitative real-time PCR combined with TaqMan copy number assays (Applied Biosystems, Foster City, CA, USA) [<xref rid="pone.0270506.ref017" ref-type="bibr">17</xref>]. CNVs identified in the database of healthy controls were removed using the ClinVar database (<ext-link xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/clinvar/</ext-link>).</p></sec><sec id="sec005"><title>Measurement of plasma pentosidine</title><p>The plasma concentration of pentosidine was measured by high-performance liquid chromatography; 55.2 ng/mL was set as the cut-off to define the PEN-SCZ and non-PEN-SCZ groups as described previously [<xref rid="pone.0270506.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0270506.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0270506.ref018" ref-type="bibr">18</xref>].</p></sec><sec id="sec006"><title>Clinical characteristics of shared CNV carriers in PEN-SCZ</title><p>The clinical characteristics of PEN-SCZ cases with shared CNVs obtained through assessment of medical records included the existence of developmental delay, autistic features, epilepsy, age at onset, psychiatric symptoms, mood symptoms, antipsychotic treatment, and presence of negative symptoms.</p></sec><sec id="sec007"><title>Statistical analysis</title><p>For demographic data, the average age, age of onset, plasma pentosidine levels, and average of chlorpromazine equivalent doses were compared by Student&#x02019;s <italic toggle="yes">t</italic>-test (two-tailed). For CNV analysis, the average of total CNV sizes and total number of genes within CNVs were assessed by Student&#x02019;s <italic toggle="yes">t</italic>-test. To evaluate the association between PEN-SCZ and shared exonic deletions, one-sided Fisher&#x02019;s exact tests were used. If no variants were found in the two-by-two table, the OR was calculated after a 0 cell correction to reduce bias as reported previously [<xref rid="pone.0270506.ref017" ref-type="bibr">17</xref>].</p></sec></sec><sec sec-type="results" id="sec008"><title>Results</title><sec id="sec009"><title>Exonic deletions among patients with PEN-SCZ</title><p>We investigated rare (&#x02264;1%) CNVs associated with SCZ in patients who presented with increased levels of plasma pentosidine, a biological marker for glycation and oxidative stress (PEN-SCZ), to identify novel drug targets for treating PEN-SCZ. A total of 185 patients with SCZ harboring rare CNVs was separated into two groups based on their plasma pentosidine levels (cut-off value; 55.2 ng/mL): 94 patients with PEN-SCZ and 91 patients with non-PEN-SCZ (<xref rid="pone.0270506.g001" ref-type="fig">Fig 1</xref>). The PEN-SCZ group harbored shared CNVs such as deletion in 7q31.1 and duplication in 16p13.13, which were not observed in control or non-PEN-SCZ subjects (<xref rid="pone.0270506.t002" ref-type="table">Table 2</xref>).</p><fig position="float" id="pone.0270506.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0270506.g001</object-id><label>Fig 1</label><caption><title>Deletions in <italic toggle="yes">IMMP2L</italic> across various neuropsychiatric disorders.</title><p>A summary of the findings, including those of previous studies and this study, on <italic toggle="yes">IMMP2L</italic> deletions across neuropsychiatric disorders, is presented. Exonic deletion in <italic toggle="yes">IMMP2L</italic> tends to span from exons 1 to 3 across neuropsychiatric disorders including ASD, GTS, ADHD, and OCD. PEN-SCZ-related deletions found in this study were also restricted to exons 1&#x02013;3. ASD: autism spectrum disorder; ADHD: attention-deficit hyperactivity disorder; BPD: bipolar disorder; GTS: Gilles de la Tourette syndrome; OCD: obsessive-compulsive disorder; PEN-SCZ: schizophrenia with accumulation of pentosidine in the plasma.</p></caption><graphic xlink:href="pone.0270506.g001" position="float"/></fig><table-wrap position="float" id="pone.0270506.t002"><object-id pub-id-type="doi">10.1371/journal.pone.0270506.t002</object-id><label>Table 2</label><caption><title>Rare CNVs and clinical features in patients with SCZ with and without accumulation of plasma pentosidine.</title></caption><alternatives><graphic xlink:href="pone.0270506.t002" id="pone.0270506.t002g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="3" colspan="1">ID</th><th align="justify" rowspan="3" colspan="1">Group</th><th align="center" colspan="4" rowspan="1">Demographics</th><th align="center" colspan="7" rowspan="1">CNV</th><th align="center" rowspan="1" colspan="1">Clinical manifestations</th></tr><tr><th align="justify" colspan="2" rowspan="2">Pentosidine (ng/mL)</th><th align="justify" rowspan="2" colspan="1">Sex</th><th align="justify" rowspan="2" colspan="1">Age</th><th align="justify" rowspan="2" colspan="1">Location</th><th align="justify" rowspan="2" colspan="1">Cytoband</th><th align="justify" rowspan="1" colspan="1">Region</th><th align="justify" rowspan="2" colspan="1">Size (bp)</th><th align="justify" rowspan="2" colspan="1">Type</th><th align="justify" rowspan="2" colspan="1">Genic</th><th align="justify" rowspan="2" colspan="1">Exonic/Intronic</th><th align="justify" rowspan="2" colspan="1">ASD features</th></tr><tr><th align="left" rowspan="1" colspan="1">Dec. 2013 (GRCH38/hg38)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patient I</td><td align="left" rowspan="1" colspan="1">PEN-SCZ</td><td align="left" rowspan="1" colspan="1">83.91</td><td align="left" rowspan="1" colspan="1">high</td><td align="left" rowspan="1" colspan="1">female</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">chr7:111431428&#x02013;111618385</td><td align="left" rowspan="1" colspan="1">7q31.1</td><td align="left" rowspan="1" colspan="1">chr7:111431428&#x02013;111618385</td><td align="left" rowspan="1" colspan="1">186957</td><td align="left" rowspan="1" colspan="1">Del</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">IMMP2L</italic>
</td><td align="left" rowspan="1" colspan="1">exons 1,2,3</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Patient II</td><td align="left" rowspan="1" colspan="1">PEN-SCZ</td><td align="left" rowspan="1" colspan="1">82.96</td><td align="left" rowspan="1" colspan="1">high</td><td align="left" rowspan="1" colspan="1">male</td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">chr7:111431428&#x02013;111618385</td><td align="left" rowspan="1" colspan="1">7q31.1</td><td align="left" rowspan="1" colspan="1">chr7:111431428&#x02013;111618385</td><td align="left" rowspan="1" colspan="1">186957</td><td align="left" rowspan="1" colspan="1">Del</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">IMMP2L</italic>
</td><td align="left" rowspan="1" colspan="1">exons 1,2,3</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">Patient III</td><td align="left" rowspan="1" colspan="1">PEN-SCZ</td><td align="left" rowspan="1" colspan="1">64.45</td><td align="left" rowspan="1" colspan="1">high</td><td align="left" rowspan="1" colspan="1">male</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">chr7:111453103&#x02013;111544709</td><td align="left" rowspan="1" colspan="1">7q31.1</td><td align="left" rowspan="1" colspan="1">chr7:111453103&#x02013;111544709</td><td align="left" rowspan="1" colspan="1">91606</td><td align="left" rowspan="1" colspan="1">Del</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">IMMP2L</italic>
</td><td align="left" rowspan="1" colspan="1">exons 2,3</td><td align="left" rowspan="1" colspan="1">Limited social skill</td></tr><tr><td align="left" rowspan="1" colspan="1">Patient IV</td><td align="left" rowspan="1" colspan="1">Non-PEN-SCZ</td><td align="left" rowspan="1" colspan="1">45.39</td><td align="left" rowspan="1" colspan="1">normal</td><td align="left" rowspan="1" colspan="1">male</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">chr7:111509431&#x02013;111521305</td><td align="left" rowspan="1" colspan="1">7q31.1</td><td align="left" rowspan="1" colspan="1">chr7:111509431&#x02013;111521305</td><td align="left" rowspan="1" colspan="1">11874</td><td align="left" rowspan="1" colspan="1">Del</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">IMMP2L</italic>
</td><td align="left" rowspan="1" colspan="1">intron 3</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="2" colspan="1">Patient V</td><td align="left" rowspan="2" colspan="1">PEN-SCZ</td><td align="left" rowspan="2" colspan="1">89.543</td><td align="left" rowspan="2" colspan="1">high</td><td align="left" rowspan="2" colspan="1">female</td><td align="left" rowspan="2" colspan="1">56</td><td align="left" rowspan="2" colspan="1">chr16:11729544&#x02013;11754368</td><td align="left" rowspan="2" colspan="1">16p13.13</td><td align="left" rowspan="2" colspan="1">chr16:11729544&#x02013;11754368</td><td align="left" rowspan="2" colspan="1">24824</td><td align="left" rowspan="2" colspan="1">Dup</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">TXNDC11</italic>,</td><td align="left" rowspan="2" colspan="1">exonic</td><td align="left" rowspan="2" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ZC3H7A</italic>
</td></tr><tr><td align="left" rowspan="2" colspan="1">Patient VI</td><td align="left" rowspan="2" colspan="1">PEN-SCZ</td><td align="left" rowspan="2" colspan="1">189.34</td><td align="left" rowspan="2" colspan="1">high</td><td align="left" rowspan="2" colspan="1">female</td><td align="left" rowspan="2" colspan="1">60</td><td align="left" rowspan="2" colspan="1">chr16:11729544&#x02013;11754368</td><td align="left" rowspan="2" colspan="1">16p13.13</td><td align="left" rowspan="2" colspan="1">chr16:11729544&#x02013;11754368</td><td align="left" rowspan="2" colspan="1">24824</td><td align="left" rowspan="2" colspan="1">Dup</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">TXNDC11</italic>,</td><td align="left" rowspan="2" colspan="1">exonic</td><td align="left" rowspan="2" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ZC3H7A</italic>
</td></tr><tr><td align="left" rowspan="2" colspan="1">Patient VII</td><td align="left" rowspan="2" colspan="1">PEN-SCZ</td><td align="left" rowspan="2" colspan="1">106.62</td><td align="left" rowspan="2" colspan="1">high</td><td align="left" rowspan="2" colspan="1">female</td><td align="left" rowspan="2" colspan="1">46</td><td align="left" rowspan="2" colspan="1">chr16:11729544&#x02013;11754368</td><td align="left" rowspan="2" colspan="1">16p13.13</td><td align="left" rowspan="2" colspan="1">chr16:11729544&#x02013;11754368</td><td align="left" rowspan="2" colspan="1">24824</td><td align="left" rowspan="2" colspan="1">Dup</td><td align="left" rowspan="1" colspan="1"><italic toggle="yes">TXNDC11</italic>,</td><td align="left" rowspan="2" colspan="1">exonic</td><td align="left" rowspan="2" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ZC3H7A</italic>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>ASD: autism spectrum disorder; CNV: copy number variation; PEN: pentosidine; SCZ: schizophrenia; Del: deletion</p></fn></table-wrap-foot></table-wrap><p>Regarding the CNV in 7q31.1, although it was not significant, deletions in <italic toggle="yes">IMMP2L</italic> exons 2 and 3 were detected in three patients with PEN-SCZ whose plasma pentosidine levels were 83.91, 82.96, and 64.45 ng/mL, respectively (p = 0.135, <xref rid="pone.0270506.t002" ref-type="table">Table 2</xref>). Patients I and II with PEN-SCZ harbored the same deletion spanning <italic toggle="yes">IMMP2L</italic> exons 1&#x02013;3, with a length of 186,957 bp from chromosome (Chr.) 7: 111,431,428 to 111,618,385. Patient III with PEN-SCZ had a deletion in <italic toggle="yes">IMMP2L</italic> exons 2 and 3 (<xref rid="pone.0270506.t002" ref-type="table">Table 2</xref>). One non-PEN-SCZ subject had a microdeletion in 7q31.1, which included an <italic toggle="yes">IMMP2L</italic> intronic region (patient IV, <xref rid="pone.0270506.g002" ref-type="fig">Fig 2</xref>). Duplication of 16p13.13, another shared CNV in three patients with PEN-SCZ, included exons of <italic toggle="yes">TXNDC11</italic> and <italic toggle="yes">ZC3H7A</italic>, which encode the thioredoxin domain containing 11 and CCCH-type zinc finger containing 7A, respectively (<xref rid="pone.0270506.t002" ref-type="table">Table 2</xref>).</p><fig position="float" id="pone.0270506.g002"><object-id pub-id-type="doi">10.1371/journal.pone.0270506.g002</object-id><label>Fig 2</label><caption><title>Clinical manifestation of schizophrenia with enhanced glycation stress harboring deletion in <italic toggle="yes">IMMP2L</italic> at 7q31.1.</title><p>We observed a shared exonic deletion in <italic toggle="yes">IMMP2L</italic> exons 2 and 3 in three patients with SCZ presenting with accumulation of pentosidine in the plasma, although it was not significant. Patients with SCZ harboring deletions spanning exons 2 and 3 in <italic toggle="yes">IMMP2L</italic> showed autistic features, such as limited social communication skills and repetitive, obsessive behavior in addition to psychosis.</p></caption><graphic xlink:href="pone.0270506.g002" position="float"/></fig><p>Among the three genes disrupted by the shared CNVs, <italic toggle="yes">IMMP2L</italic> was a recurrent SCZ risk gene found in the previous SCZ genome-wide association study conducted by the PGC. Hence, we assessed whether the clinical features were shared among the three patients with PEN-SCZ harboring exonic deletions in <italic toggle="yes">IMMP2L</italic>, although its association was not significant, possibly because of the small sample size.</p></sec><sec id="sec010"><title>Clinical characteristics of patients with PEN-SCZ harboring exonic deletions in <italic toggle="yes">IMMP2L</italic></title><p>According to clinical records, shared clinical characteristics among the patients with PEN-SCZ were observed. For example, in addition to psychosis, the three patients harboring a deletion in <italic toggle="yes">IMMP2L</italic> exons 2 and 3 had autistic features (<xref rid="pone.0270506.t002" ref-type="table">Table 2</xref>). Patient I was diagnosed with autism spectrum disorder (ASD) in addition to SCZ, and her social communication skills were extremely limited since childhood. Patient III also showed limited social skills since childhood and is currently considered to be a SCZ subtype for which most prominent symptoms were negative symptoms. Patient II also showed a limited social communication capability with repetitive behaviors since childhood.</p></sec></sec><sec sec-type="conclusions" id="sec011"><title>Discussion</title><p>In this study, we observed the shared 7q31.1 deletion spanning exons 2 and 3 in <italic toggle="yes">IMMP2L</italic>, known as one of the SCZ risk genes, among a subtype of SCZ with enhanced glycation and oxidative stress (PEN-SCZ), presenting with additional ASD phenotypes or limited social capability, although the association was not significant. Interestingly, deletion or duplication in other exons or introns of <italic toggle="yes">IMMP2L</italic> did not affect the plasma pentosidine level. Another CNV, a duplication at 16p13.13, was identified as a candidate for a shared genetic background in other PEN-SCZ cases, disrupting <italic toggle="yes">TXNDC11</italic> and <italic toggle="yes">ZC3H7A</italic>.</p><sec id="sec012"><title><italic toggle="yes">IMMP2L</italic> deletions and neuropsychiatric disorders</title><p>IMMP2L, inner mitochondrial membrane peptidase 2-like, is a mitochondrial enzyme critical for glycolysis as the main pathway using glucose to respond to energy demands in the brain. <italic toggle="yes">IMMP2L</italic> knockdown in primary astrocytes leads to dysregulation of genes involved in brain development [<xref rid="pone.0270506.ref019" ref-type="bibr">19</xref>]. CNVs or genomic variations disrupting <italic toggle="yes">IMMP2L</italic> have been reported across neurodevelopmental psychiatric disorders, including SCZ [<xref rid="pone.0270506.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0270506.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0270506.ref020" ref-type="bibr">20</xref>&#x02013;<xref rid="pone.0270506.ref022" ref-type="bibr">22</xref>], ASD [<xref rid="pone.0270506.ref023" ref-type="bibr">23</xref>&#x02013;<xref rid="pone.0270506.ref025" ref-type="bibr">25</xref>], attention-deficit hyperactivity disorder (ADHD) [<xref rid="pone.0270506.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0270506.ref027" ref-type="bibr">27</xref>], and Gilles de la Tourette syndrome (GTS) [<xref rid="pone.0270506.ref028" ref-type="bibr">28</xref>&#x02013;<xref rid="pone.0270506.ref030" ref-type="bibr">30</xref>]. We summarized past and present findings on <italic toggle="yes">IMMP2L</italic> deletions across neuropsychiatric disorders (<xref rid="pone.0270506.g001" ref-type="fig">Fig 1</xref>); the results suggested that behavioral phenotypes vary depending on the exons disrupted by CNVs in <italic toggle="yes">IMMP2L</italic>. Interestingly, exonic deletions in <italic toggle="yes">IMMP2L</italic> tend to span from exons 1 to 3 across various neuropsychiatric disorders, including ASD, GTS, ADHD, and OCD but excluding bipolar disorder. PEN-SCZ-related deletions found in this study also appeared to be restricted to exons 1 to 3 (<xref rid="pone.0270506.g001" ref-type="fig">Fig 1</xref>). To investigate the effect of the CNV deletion on <italic toggle="yes">IMMP2L</italic> in patients with SCZ, we examined possibility if any proteins could be produced from the allele of <italic toggle="yes">IMMP2L</italic> with the exon deletions. We found no open reading frames with enough length, as the lengths of exon 2, exon 3, and their totals are not multiple of three (that is, 137nt, 104nt, and 241nt). To assess if any compensation effect happened from the allele with no deletions, we measured <italic toggle="yes">IMMP2L</italic> mRNA in whole blood cells from patients with SCZ and a control subject. Our data indicated that the <italic toggle="yes">IMMP2L</italic> full-length form tended to be lower in patients with CNV deletion than that in a healthy individual without the CNV deletion, suggesting no compensation at the level of RNA (<xref rid="pone.0270506.s001" ref-type="supplementary-material">S1 Fig</xref>). Furthermore, in order to evaluate the possibility of loss-of-function and gain-of-function, we conducted a western blot experiment on the C-terminal antibody of IMMP2L protein. However, due to the lack of detectable <italic toggle="yes">IMMP2L</italic> expression in PBMC, definite truncated-form were not observed in a wild-type control subject.</p></sec><sec id="sec013"><title><italic toggle="yes">IMMP2L</italic> and schizophrenia</title><p>Notably, <italic toggle="yes">IMMP2L</italic> is an SCZ risk loci gene identified by the PGC in the previous SCZ-genome-wide association study (rank 15, p = 3.034 &#x000d7; 10<sup>&#x02212;13</sup>) [<xref rid="pone.0270506.ref009" ref-type="bibr">9</xref>]. Ikeda et al. confirmed the trans-populational association between <italic toggle="yes">IMMP2L</italic> rs214467 and SCZ (p = 4.74 &#x000d7; 10<sup>&#x02212;11</sup>) [<xref rid="pone.0270506.ref013" ref-type="bibr">13</xref>]. Moreover, association analysis of the 108 SCZ risk loci and cognitive functions revealed the most significant associations between rs13240464 within <italic toggle="yes">IMMP2L</italic> and &#x0201c;delayed recall&#x0201d; and &#x0201c;visual memory [<xref rid="pone.0270506.ref031" ref-type="bibr">31</xref>]. Taken together with our results from a pilot study with a small sample size, both common and rare <italic toggle="yes">IMMP2L</italic> variants may be involved in the SCZ etiology. Previous studies revealed that <italic toggle="yes">IMMP2L</italic> exon 6 transcripts were expressed across brain regions, including in the hippocampus, temporal lobe, and thalamus [<xref rid="pone.0270506.ref029" ref-type="bibr">29</xref>]. These transcripts are relevant to cognitive function and sensory gating and have been shown to be disrupted in patients with SCZ; however, other exons have not been fully investigated. In postmortem brain studies of SCZ, expression of glycerol-3-phosphate dehydrogenase 2, the substrate for <italic toggle="yes">IMMP2L</italic>, has been reported to be altered in the anterior cingulate cortex [<xref rid="pone.0270506.ref032" ref-type="bibr">32</xref>]. Although we did not observe a significant association between rare exonic deletions in <italic toggle="yes">IMMP2L</italic> and PEN-SCZ, given our small sample size, <italic toggle="yes">IMMP2L</italic> is a candidate therapeutic target in PEN-SCZ, particularly for the improvement of memory function; however, this should be evaluated in a larger sample size.</p></sec><sec id="sec014"><title>Clinical characteristics of <italic toggle="yes">IMMP2L</italic> deletion carriers in PEN-SCZ</title><p>Patients harboring the 7q31.1 deletion, which includes <italic toggle="yes">IMMP2L</italic>, have been reported to present some repetitive behavioral phenotypes and/or obsessive-compulsive symptoms observed in ASD [<xref rid="pone.0270506.ref025" ref-type="bibr">25</xref>], obsessive-compulsive disorder, and GTS [<xref rid="pone.0270506.ref028" ref-type="bibr">28</xref>, <xref rid="pone.0270506.ref029" ref-type="bibr">29</xref>]. ASD is characterized by reduced reciprocal social interaction, an impaired ability to communicate, a narrow range of interests, and repetitive behaviors. Baldan et al. identified two patients with ASD who harbored deletions in <italic toggle="yes">IMMP2L</italic> from exons 1 to 3 and in introns (<xref rid="pone.0270506.g002" ref-type="fig">Fig 2</xref>) [<xref rid="pone.0270506.ref025" ref-type="bibr">25</xref>]. Zhang et al. genotyped 100 trio families that included patients with ASD in a Han Chinese population and identified three cases carrying rare <italic toggle="yes">IMMP2L</italic> exonic deletions [<xref rid="pone.0270506.ref024" ref-type="bibr">24</xref>]. In a Danish cohort study investigating CNVs in 188 unrelated patients with Tourette syndrome, seven patients were found to have <italic toggle="yes">IMMP2L</italic> deletions, which were also restricted to exons 1&#x02013;3 (<xref rid="pone.0270506.g001" ref-type="fig">Fig 1</xref>) [<xref rid="pone.0270506.ref029" ref-type="bibr">29</xref>].</p><p>In this study, PEN-SCZ patients I and II, who carried deletions in <italic toggle="yes">IMMP2L</italic> exons 1&#x02013;3, presented with additional autistic features, including limited social communication skills in addition to psychosis (<xref rid="pone.0270506.t002" ref-type="table">Table 2</xref>). Interestingly, a previous animal study demonstrated that <italic toggle="yes">IMMP2L</italic> knockout mice displayed behavioral changes in social interactions linked to both limited social skills in ASD and negative symptoms in SCZ [<xref rid="pone.0270506.ref033" ref-type="bibr">33</xref>]. Limited social skills in ASD may be broadly linked to negative symptoms in SCZ, in terms of their biological aspects associated with possibly impaired <italic toggle="yes">IMMP2L</italic> function. Supporting this notion, animal studies demonstrated dysfunction of the dopamine system in <italic toggle="yes">IMMP2L</italic> knockout mice [<xref rid="pone.0270506.ref033" ref-type="bibr">33</xref>]; therefore, an <italic toggle="yes">IMMP2L</italic> modulator may improve both the autistic features and limited social communication capacity.</p></sec><sec id="sec015"><title><italic toggle="yes">IMMP2L</italic> and glycation/oxidative stress</title><p>A mutant mouse model of <italic toggle="yes">IMMP2L</italic> has been reported to show elevated mitochondrial reactive oxygen species and an increased plasma carbonyl content, both of which reflect glycation and oxidative stress [<xref rid="pone.0270506.ref034" ref-type="bibr">34</xref>]. <italic toggle="yes">IMMP2L</italic> deficiency in the brain mitochondria has been shown to critically affect normal brain function [<xref rid="pone.0270506.ref035" ref-type="bibr">35</xref>]. In our reverse transcription-PCR experiment, gene expression levels of <italic toggle="yes">IMMP2L</italic> were lower in <italic toggle="yes">IMMP2L</italic>-deficient cases compared to wild type (<xref rid="pone.0270506.s001" ref-type="supplementary-material">S1 Fig</xref>). Immp2l deficiency has been shown to enhance production of superoxide and to have damaging effect on the mitochondrial function that may lead enhanced glycation stress [<xref rid="pone.0270506.ref035" ref-type="bibr">35</xref>].</p><p>Interestingly, <italic toggle="yes">IMMP2L</italic> mutant mice developed neuronal degeneration in an age-dependent manner [<xref rid="pone.0270506.ref036" ref-type="bibr">36</xref>]. Mitochondrial reactive oxygen species have been implicated in age-related disorders, such as neurodegenerative diseases, including Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease [<xref rid="pone.0270506.ref037" ref-type="bibr">37</xref>]. Mitochondria-targeting antioxidant skQ1 has been shown to rescue age-dependent neurodegeneration in an <italic toggle="yes">IMMP2L</italic> mutant mouse model [<xref rid="pone.0270506.ref036" ref-type="bibr">36</xref>]. Studies are needed to determine whether the SCZ behavioral phenotype can be rescued by skQ1 in a mouse model of SCZ with enhanced glycation/oxidative stress.</p><p>In the present study, we aimed to clarify the molecular mechanisms that cause the accumulation of pentosidine. In four cases with CNV deletion, a subsequent pentosidine accumulation was expected, but it could not be confirmed in a patient IV. This observation suggests that an unknown <italic toggle="yes">IMMP2L</italic> independent molecular pathway was involved in the pentosidine alteration. Due to difficulty in re-recruiting a patient IV, we were unable to conduct further analysis. In the future, a higher number of patients must be considered for further investigation and the link between the <italic toggle="yes">IMMP2L</italic> deficiency and the mitochondrial dysfunctions or an accelerated reactive oxygen species and whether mechanisms for pentosidine linked to phenomenon occurs in patients with <italic toggle="yes">IMMP2L</italic> CNV should be clarified.</p></sec><sec id="sec016"><title><italic toggle="yes">TXNDC11</italic> and <italic toggle="yes">ZC3H7A</italic></title><p><italic toggle="yes">TXNDC11</italic> and <italic toggle="yes">ZC3H7A</italic> were also found to be affected by rare CNVs at 16p13.13. The 16p13.13 duplication has never been linked with SCZ; however, it has been reported in patients diagnosed with ASD [<xref rid="pone.0270506.ref038" ref-type="bibr">38</xref>], intellectual disability, developmental delay, facial asymmetry, growth deficiency, and several congenital anomalies [<xref rid="pone.0270506.ref039" ref-type="bibr">39</xref>]. <italic toggle="yes">TXNDC11</italic> encodes a thioredoxin domain containing 11, known as an endoplasmic reticulum-resident thioredoxin domain protein [<xref rid="pone.0270506.ref040" ref-type="bibr">40</xref>]. Thioredoxin is an intrinsic antioxidant system and <italic toggle="yes">TXNDC11</italic> may act as a redox regulator involved in DUOX protein folding [<xref rid="pone.0270506.ref040" ref-type="bibr">40</xref>]. In redox homeostasis, <italic toggle="yes">TXNDX11</italic> may be involved in the accumulation of plasma pentosidine in PEN-SCZ.</p><p><italic toggle="yes">ZC3H7A</italic> encodes zinc finger CCCH-type containing 7A and has been shown to be a crucial regulator of immune responses [<xref rid="pone.0270506.ref041" ref-type="bibr">41</xref>] through the regulation of cytokine production, immune cell activation, immune homeostasis, and antiviral responses [<xref rid="pone.0270506.ref042" ref-type="bibr">42</xref>]. Although genetic associations between SCZ and <italic toggle="yes">ZC3H7A</italic> have never been reported, further investigation of the relationship between <italic toggle="yes">ZC3H7A</italic> and the pathophysiology of SCZ would be of interest in terms of immune system disturbance, which has also been strongly implicated in SCZ.</p></sec><sec id="sec017"><title>Limitations</title><p>A major strength of this study is that it was an integrative study investigating CNVs with metabolomes, which provided insights into the pathophysiology of PEN-SCZ and led to the identification of a shared genetic background for this biological subtype. However, there were some limitations. First, the sample size was small; thus, further research of a larger sample size is needed to examine the involvement of <italic toggle="yes">IMMP2L</italic> in the etiology of PEN-SCZ. Second, as we only investigated rare CNVs as a genetic background, other genetic and epigenetic factors that account for enhanced glycation and oxidative stress must be investigated to clarify the whole picture of PEN-SCZ etiology. Third, patients with PEN-SCZ were significantly older and taking more medications than non-PEN-SCZ subjects. It is possible that pentosidine elevates as a function of age or medication in this population.</p></sec></sec><sec sec-type="conclusions" id="sec018"><title>Conclusions</title><p>We identified shared exonic deletion in exons 2 and 3 in <italic toggle="yes">IMMP2L</italic>, a recurrent SCZ risk locus gene, among three PEN-SCZ cases presenting with additional ASD phenotypes or limited social capability. Future research of a larger sample size is warranted to validate the association, as it was not significant possibly because of the small sample size. Experimental validation of the involvement of <italic toggle="yes">IMMP2L</italic> exonic deletion in plasma pentosidine accumulation should also be examined. Additionally, accumulation of genetic data linked with omics and phenotypic profiles would improve the definition of the biological subtypes of SCZ.</p></sec><sec id="sec019" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0270506.s001" position="float" content-type="local-data"><label>S1 Fig</label><caption><title>RT-PCR analysis of <italic toggle="yes">IMMP2L</italic> levels.</title><p>As shown in RT-PCR experiments, we confirmed that expression levels were lower in <italic toggle="yes">IMMP2L</italic>-deficient cases compared to wild type.</p><p>(TIF)</p></caption><media xlink:href="pone.0270506.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We are grateful for the expert technical assistance of Nanako Obata, Izumi Nohara, Mai Hatakenaka, Yukiko Shimada, Chikako Ishida, and Ikuyo Kito. We would especially like to thank Hiroko Yuzawa and Shunya Takizawa at Tokai University School of Medicine for the measurement of pentosidine levels. We are grateful to all families who participated in this study.</p></ack><ref-list><title>References</title><ref id="pone.0270506.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Tsuang</surname><given-names>MT</given-names></name>, <name><surname>Lyons</surname><given-names>MJ</given-names></name>, <name><surname>Faraone</surname><given-names>SV</given-names></name>. <article-title>Heterogeneity of schizophrenia</article-title>. <source>Br J Psychiatry</source>. <year>1990</year>;<volume>156</volume>(<issue>1</issue>): <fpage>17</fpage>&#x02013;<lpage>26</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1192/bjp.156.1.17</pub-id>
<pub-id pub-id-type="pmid">2404538</pub-id></mixed-citation></ref><ref id="pone.0270506.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Buckley</surname><given-names>PF</given-names></name>, <name><surname>Miller</surname><given-names>BJ</given-names></name>. <article-title>Personalized medicine for schizophrenia</article-title>. <source>npg Schizophr</source>. <year>2017</year>;<volume>3</volume>(<issue>2</issue>).</mixed-citation></ref><ref id="pone.0270506.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Arai</surname><given-names>M</given-names></name>, <name><surname>Yuzawa</surname><given-names>H</given-names></name>, <name><surname>Nohara</surname><given-names>I</given-names></name>, <name><surname>Ohnishi</surname><given-names>T</given-names></name>, <name><surname>Obata</surname><given-names>N</given-names></name>, <name><surname>Iwayama</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Enhanced carbonyl stress in a subpopulation of schizophrenia</article-title>. <source>Arch Gen Psychiatry</source>. <year>2010</year>;<volume>67</volume>(<issue>6</issue>): <fpage>589</fpage>&#x02013;<lpage>597</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2010.62</pub-id>
<pub-id pub-id-type="pmid">20530008</pub-id></mixed-citation></ref><ref id="pone.0270506.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Singh</surname><given-names>R</given-names></name>, <name><surname>Barden</surname><given-names>A</given-names></name>, <name><surname>Mori</surname><given-names>T</given-names></name>, <name><surname>Beilin</surname><given-names>L</given-names></name>. <article-title>Advanced glycation end-products: a review</article-title>. <source>Diabetologia</source>. <year>2001</year>;<volume>44</volume>(<issue>2</issue>): <fpage>129</fpage>&#x02013;<lpage>146</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s001250051591</pub-id>
<pub-id pub-id-type="pmid">11270668</pub-id></mixed-citation></ref><ref id="pone.0270506.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Itokawa</surname><given-names>M</given-names></name>, <name><surname>Miyashita</surname><given-names>M</given-names></name>, <name><surname>Arai</surname><given-names>M</given-names></name>, <name><surname>Dan</surname><given-names>T</given-names></name>, <name><surname>Takahashi</surname><given-names>K</given-names></name>, <name><surname>Tokunaga</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress</article-title>. <source>Psychiatry Clin Neurosci</source>. <year>2018</year>;<volume>72</volume>(<issue>1</issue>): <fpage>35</fpage>&#x02013;<lpage>44</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/pcn.12613</pub-id>
<pub-id pub-id-type="pmid">29064136</pub-id></mixed-citation></ref><ref id="pone.0270506.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>McGuffin</surname><given-names>P</given-names></name>, <name><surname>Owen</surname><given-names>M</given-names></name>. <article-title>Genetic basis of schizophrenia</article-title>. <source>Lancet</source>. <year>1995</year>;<volume>346</volume>(<issue>8976</issue>): <fpage>678</fpage>&#x02013;<lpage>682</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0140-6736(95)92285-7</pub-id>
<pub-id pub-id-type="pmid">7658823</pub-id></mixed-citation></ref><ref id="pone.0270506.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Hilker</surname><given-names>R</given-names></name>, <name><surname>Helenius</surname><given-names>D</given-names></name>, <name><surname>Fagerlund</surname><given-names>B</given-names></name>, <name><surname>Skytthe</surname><given-names>A</given-names></name>, <name><surname>Christensen</surname><given-names>K</given-names></name>, <name><surname>Werge</surname><given-names>TM</given-names></name>, <etal>et al</etal>. <article-title>Heritability of schizophrenia and schizophrenia spectrum based on the nationwide Danish twin register</article-title>. <source>Biol Psychiatry</source>. <year>2018</year>;<volume>83</volume>(<issue>6</issue>): <fpage>492</fpage>&#x02013;<lpage>498</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.biopsych.2017.08.017</pub-id>
<pub-id pub-id-type="pmid">28987712</pub-id></mixed-citation></ref><ref id="pone.0270506.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Stefansson</surname><given-names>H</given-names></name>, <name><surname>Ophoff</surname><given-names>RA</given-names></name>, <name><surname>Steinberg</surname><given-names>S</given-names></name>, <name><surname>Andreassen</surname><given-names>OA</given-names></name>, <name><surname>Cichon</surname><given-names>S</given-names></name>, <name><surname>Rujescu</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Common variants conferring risk of schizophrenia</article-title>. <source>Nature</source>. <year>2009</year>;<volume>460</volume>(<issue>7256</issue>): <fpage>744</fpage>&#x02013;<lpage>747</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature08186</pub-id>
<pub-id pub-id-type="pmid">19571808</pub-id></mixed-citation></ref><ref id="pone.0270506.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Ripke</surname><given-names>S</given-names></name>, <name><surname>Neale</surname><given-names>BM</given-names></name>, <name><surname>Corvin</surname><given-names>A</given-names></name>, <name><surname>Walters</surname><given-names>JT</given-names></name>, <name><surname>Farh</surname><given-names>K-H</given-names></name>, <name><surname>Holmans</surname><given-names>PA</given-names></name>, <etal>et al</etal>. <article-title>Biological insights from 108 schizophrenia-associated genetic loci</article-title>. <source>Nature</source>. <year>2014</year>;<volume>511</volume>(<issue>7510</issue>): <fpage>421</fpage>&#x02013;<lpage>427</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature13595</pub-id>
<pub-id pub-id-type="pmid">25056061</pub-id></mixed-citation></ref><ref id="pone.0270506.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Consortium</surname><given-names>IS</given-names></name>. <article-title>Rare chromosomal deletions and duplications increase risk of schizophrenia</article-title>. <source>Nature</source>. <year>2008</year>;<volume>455</volume>(<issue>7210</issue>): <fpage>237</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature07239</pub-id>
<pub-id pub-id-type="pmid">18668038</pub-id></mixed-citation></ref><ref id="pone.0270506.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Genovese</surname><given-names>G</given-names></name>, <name><surname>Fromer</surname><given-names>M</given-names></name>, <name><surname>Stahl</surname><given-names>EA</given-names></name>, <name><surname>Ruderfer</surname><given-names>DM</given-names></name>, <name><surname>Chambert</surname><given-names>K</given-names></name>, <name><surname>Land&#x000e9;n</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia</article-title>. <source>Nat Neurosci</source>. <year>2016</year>;<volume>19</volume>(<issue>11</issue>): <fpage>1433</fpage>&#x02013;<lpage>1441</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nn.4402</pub-id>
<pub-id pub-id-type="pmid">27694994</pub-id></mixed-citation></ref><ref id="pone.0270506.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Purcell</surname><given-names>SM</given-names></name>, <name><surname>Moran</surname><given-names>JL</given-names></name>, <name><surname>Fromer</surname><given-names>M</given-names></name>, <name><surname>Ruderfer</surname><given-names>D</given-names></name>, <name><surname>Solovieff</surname><given-names>N</given-names></name>, <name><surname>Roussos</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>A polygenic burden of rare disruptive mutations in schizophrenia</article-title>. <source>Nature</source>. <year>2014</year>;<volume>506</volume>(<issue>7487</issue>): <fpage>185</fpage>&#x02013;<lpage>190</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature12975</pub-id>
<pub-id pub-id-type="pmid">24463508</pub-id></mixed-citation></ref><ref id="pone.0270506.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Ikeda</surname><given-names>M</given-names></name>, <name><surname>Takahashi</surname><given-names>A</given-names></name>, <name><surname>Kamatani</surname><given-names>Y</given-names></name>, <name><surname>Momozawa</surname><given-names>Y</given-names></name>, <name><surname>Saito</surname><given-names>T</given-names></name>, <name><surname>Kondo</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Genome-wide association study detected novel susceptibility genes for schizophrenia and shared trans-populations/diseases genetic effect</article-title>. <source>Schizophr Bull</source>. <year>2019</year>;<volume>45</volume>(<issue>4</issue>): <fpage>824</fpage>&#x02013;<lpage>834</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/schbul/sby140</pub-id>
<pub-id pub-id-type="pmid">30285260</pub-id></mixed-citation></ref><ref id="pone.0270506.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Walsh</surname><given-names>T</given-names></name>, <name><surname>McClellan</surname><given-names>JM</given-names></name>, <name><surname>McCarthy</surname><given-names>SE</given-names></name>, <name><surname>Addington</surname><given-names>AM</given-names></name>, <name><surname>Pierce</surname><given-names>SB</given-names></name>, <name><surname>Cooper</surname><given-names>GM</given-names></name>, <etal>et al</etal>. <article-title>Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia</article-title>. <source>Science</source>. <year>2008</year>;<volume>320</volume>(<issue>5875</issue>): <fpage>539</fpage>&#x02013;<lpage>543</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.1155174</pub-id>
<pub-id pub-id-type="pmid">18369103</pub-id></mixed-citation></ref><ref id="pone.0270506.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Malhotra</surname><given-names>D</given-names></name>, <name><surname>Sebat</surname><given-names>J</given-names></name>. <article-title>CNVs: harbingers of a rare variant revolution in psychiatric genetics</article-title>. <source>Cell</source>. <year>2012</year>;<volume>148</volume>(<issue>6</issue>): <fpage>1223</fpage>&#x02013;<lpage>1241</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.039</pub-id>
<pub-id pub-id-type="pmid">22424231</pub-id></mixed-citation></ref><ref id="pone.0270506.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Marshall</surname><given-names>CR</given-names></name>, <name><surname>Howrigan</surname><given-names>DP</given-names></name>, <name><surname>Merico</surname><given-names>D</given-names></name>, <name><surname>Thiruvahindrapuram</surname><given-names>B</given-names></name>, <name><surname>Wu</surname><given-names>W</given-names></name>, <name><surname>Greer</surname><given-names>DS</given-names></name>, <etal>et al</etal>. <article-title>Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects</article-title>. <source>Nat Genet</source>. <year>2017</year>;<volume>49</volume>(<issue>1</issue>): <fpage>27</fpage>&#x02013;<lpage>35</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ng.3725</pub-id>
<pub-id pub-id-type="pmid">27869829</pub-id></mixed-citation></ref><ref id="pone.0270506.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Kushima</surname><given-names>I</given-names></name>, <name><surname>Aleksic</surname><given-names>B</given-names></name>, <name><surname>Nakatochi</surname><given-names>M</given-names></name>, <name><surname>Shimamura</surname><given-names>T</given-names></name>, <name><surname>Okada</surname><given-names>T</given-names></name>, <name><surname>Uno</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Comparative analyses of copy-number variation in autism spectrum disorder and schizophrenia reveal etiological overlap and biological insights</article-title>. <source>Cell Rep</source>. <year>2018</year>;<volume>24</volume>(<issue>11</issue>): <fpage>2838</fpage>&#x02013;<lpage>2856</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.celrep.2018.08.022</pub-id>
<pub-id pub-id-type="pmid">30208311</pub-id></mixed-citation></ref><ref id="pone.0270506.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Miyata</surname><given-names>T</given-names></name>, <name><surname>Taneda</surname><given-names>S</given-names></name>, <name><surname>Kawai</surname><given-names>R</given-names></name>, <name><surname>Ueda</surname><given-names>Y</given-names></name>, <name><surname>Horiuchi</surname><given-names>S</given-names></name>, <name><surname>Hara</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>1996</year>;<volume>93</volume>(<issue>6</issue>): <fpage>2353</fpage>&#x02013;<lpage>2358</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.93.6.2353</pub-id>
<pub-id pub-id-type="pmid">8637877</pub-id></mixed-citation></ref><ref id="pone.0270506.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Gokoolparsadh</surname><given-names>A</given-names></name>, <name><surname>Fang</surname><given-names>Z</given-names></name>, <name><surname>Braidy</surname><given-names>N</given-names></name>, <name><surname>Lin</surname><given-names>P</given-names></name>, <name><surname>Pardy</surname><given-names>CJ</given-names></name>, <name><surname>Eapen</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Transcriptional response to mitochondrial protease IMMP2L knockdown in human primary astrocytes</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2017</year>;<volume>482</volume>(<issue>4</issue>): <fpage>1252</fpage>&#x02013;<lpage>1258</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.bbrc.2016.12.024</pub-id>
<pub-id pub-id-type="pmid">27932244</pub-id></mixed-citation></ref><ref id="pone.0270506.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Khan</surname><given-names>FF</given-names></name>, <name><surname>Melton</surname><given-names>PE</given-names></name>, <name><surname>McCarthy</surname><given-names>NS</given-names></name>, <name><surname>Morar</surname><given-names>B</given-names></name>, <name><surname>Blangero</surname><given-names>J</given-names></name>, <name><surname>Moses</surname><given-names>EK</given-names></name>, <etal>et al</etal>. <article-title>Whole genome sequencing of 91 multiplex schizophrenia families reveals increased burden of rare, exonic copy number variation in schizophrenia probands and genetic heterogeneity</article-title>. <source>Schizophr Res</source>. <year>2018</year>;<volume>197</volume>: <fpage>337</fpage>&#x02013;<lpage>345</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.schres.2018.02.034</pub-id>
<pub-id pub-id-type="pmid">29486958</pub-id></mixed-citation></ref><ref id="pone.0270506.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Consortium</surname><given-names>ISG</given-names></name>, 2 WTCCC. <article-title>Genome-wide association study implicates HLA-C* 01: 02 as a risk factor at the major histocompatibility complex locus in schizophrenia</article-title>. <source>Biol Psychiatry</source>. <year>2012</year>;<volume>72</volume>(<issue>8</issue>): <fpage>620</fpage>&#x02013;<lpage>628</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.biopsych.2012.05.035</pub-id>
<pub-id pub-id-type="pmid">22883433</pub-id></mixed-citation></ref><ref id="pone.0270506.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Goes</surname><given-names>FS</given-names></name>, <name><surname>McGrath</surname><given-names>J</given-names></name>, <name><surname>Avramopoulos</surname><given-names>D</given-names></name>, <name><surname>Wolyniec</surname><given-names>P</given-names></name>, <name><surname>Pirooznia</surname><given-names>M</given-names></name>, <name><surname>Ruczinski</surname><given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Genome&#x02010;wide association study of schizophrenia in Ashkenazi Jews</article-title>. <source>Am J Med Genet B Neuropsychiatr Genet</source>. <year>2015</year>;<volume>168</volume>(<issue>8</issue>): <fpage>649</fpage>&#x02013;<lpage>659</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/ajmg.b.32349</pub-id>
<pub-id pub-id-type="pmid">26198764</pub-id></mixed-citation></ref><ref id="pone.0270506.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Maestrini</surname><given-names>E</given-names></name>, <name><surname>Pagnamenta</surname><given-names>A</given-names></name>, <name><surname>Lamb</surname><given-names>J</given-names></name>, <name><surname>Bacchelli</surname><given-names>E</given-names></name>, <name><surname>Sykes</surname><given-names>N</given-names></name>, <name><surname>Sousa</surname><given-names>I</given-names></name>, <etal>et al</etal>. <article-title>High-density SNP association study and copy number variation analysis of the AUTS1 and AUTS5 loci implicate the IMMP2L&#x02013;DOCK4 gene region in autism susceptibility</article-title>. <source>Mol Psychiatry</source>. <year>2010</year>;<volume>15</volume>(<issue>9</issue>): <fpage>954</fpage>&#x02013;<lpage>968</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/mp.2009.34</pub-id>
<pub-id pub-id-type="pmid">19401682</pub-id></mixed-citation></ref><ref id="pone.0270506.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Zarrei</surname><given-names>M</given-names></name>, <name><surname>Tong</surname><given-names>W</given-names></name>, <name><surname>Dong</surname><given-names>R</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Association of IMMP2L deletions with autism spectrum disorder: A trio family study and meta&#x02010;analysis</article-title>. <source>Am J Med Genet B Neuropsychiatr Genet</source>. <year>2018</year>;<volume>177</volume>(<issue>1</issue>): <fpage>93</fpage>&#x02013;<lpage>100</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/ajmg.b.32608</pub-id>
<pub-id pub-id-type="pmid">29152845</pub-id></mixed-citation></ref><ref id="pone.0270506.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Baldan</surname><given-names>F</given-names></name>, <name><surname>Gnan</surname><given-names>C</given-names></name>, <name><surname>Franzoni</surname><given-names>A</given-names></name>, <name><surname>Ferino</surname><given-names>L</given-names></name>, <name><surname>Allegri</surname><given-names>L</given-names></name>, <name><surname>Passon</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Genomic deletion involving the IMMP2L gene in two cases of autism spectrum disorder</article-title>. <source>Cytogenet Genome Res</source>. <year>2018</year>;<volume>154</volume>(<issue>4</issue>): <fpage>196</fpage>&#x02013;<lpage>200</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1159/000489001</pub-id>
<pub-id pub-id-type="pmid">29788020</pub-id></mixed-citation></ref><ref id="pone.0270506.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Elia</surname><given-names>J</given-names></name>, <name><surname>Gai</surname><given-names>X</given-names></name>, <name><surname>Xie</surname><given-names>H</given-names></name>, <name><surname>Perin</surname><given-names>J</given-names></name>, <name><surname>Geiger</surname><given-names>E</given-names></name>, <name><surname>Glessner</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes</article-title>. <source>Mol Psychiatry</source>. <year>2010</year>;<volume>15</volume>(<issue>6</issue>): <fpage>637</fpage>&#x02013;<lpage>646</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/mp.2009.57</pub-id>
<pub-id pub-id-type="pmid">19546859</pub-id></mixed-citation></ref><ref id="pone.0270506.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Gimelli</surname><given-names>S</given-names></name>, <name><surname>Capra</surname><given-names>V</given-names></name>, <name><surname>Di Rocco</surname><given-names>M</given-names></name>, <name><surname>Leoni</surname><given-names>M</given-names></name>, <name><surname>Mirabelli-Badenier</surname><given-names>M</given-names></name>, <name><surname>Schiaffino</surname><given-names>MC</given-names></name>, <etal>et al</etal>. <article-title>Interstitial 7q31. 1 copy number variations disrupting IMMP2L gene are associated with a wide spectrum of neurodevelopmental disorders</article-title>. <source>Mol Cytogenet</source>. <year>2014</year>;<volume>7</volume>(<issue>1</issue>): <fpage>54</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13039-014-0054-y</pub-id>
<pub-id pub-id-type="pmid">25478008</pub-id></mixed-citation></ref><ref id="pone.0270506.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Deng</surname><given-names>H</given-names></name>, <name><surname>Gao</surname><given-names>K</given-names></name>, <name><surname>Jankovic</surname><given-names>J</given-names></name>. <article-title>The genetics of Tourette syndrome</article-title>. <source>Nat Rev Neurol</source>. <year>2012</year>;<volume>8</volume>(<issue>4</issue>): <fpage>203</fpage>&#x02013;<lpage>213</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrneurol.2012.26</pub-id>
<pub-id pub-id-type="pmid">22410579</pub-id></mixed-citation></ref><ref id="pone.0270506.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Petek</surname><given-names>E</given-names></name>, <name><surname>Windpassinger</surname><given-names>C</given-names></name>, <name><surname>Vincent</surname><given-names>JB</given-names></name>, <name><surname>Cheung</surname><given-names>J</given-names></name>, <name><surname>Boright</surname><given-names>AP</given-names></name>, <name><surname>Scherer</surname><given-names>SW</given-names></name>, <etal>et al</etal>. <article-title>Disruption of a novel gene (IMMP2L) by a breakpoint in 7q31 associated with Tourette syndrome</article-title>. <source>Am J Hum Genet</source>. <year>2001</year>;<volume>68</volume>(<issue>4</issue>): <fpage>848</fpage>&#x02013;<lpage>858</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1086/319523</pub-id>
<pub-id pub-id-type="pmid">11254443</pub-id></mixed-citation></ref><ref id="pone.0270506.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Bertelsen</surname><given-names>B</given-names></name>, <name><surname>Melchior</surname><given-names>L</given-names></name>, <name><surname>Jensen</surname><given-names>LR</given-names></name>, <name><surname>Groth</surname><given-names>C</given-names></name>, <name><surname>Glenth&#x000f8;j</surname><given-names>B</given-names></name>, <name><surname>Rizzo</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Intragenic deletions affecting two alternative transcripts of the IMMP2L gene in patients with Tourette syndrome</article-title>. <source>Eur J Hum Genet</source>. <year>2014</year>;<volume>22</volume>(<issue>11</issue>): <fpage>1283</fpage>&#x02013;<lpage>1289</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ejhg.2014.24</pub-id>
<pub-id pub-id-type="pmid">24549057</pub-id></mixed-citation></ref><ref id="pone.0270506.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Maul</surname><given-names>S</given-names></name>, <name><surname>Konte</surname><given-names>B</given-names></name>, <name><surname>Hartmann</surname><given-names>A</given-names></name>, <name><surname>Giegling</surname><given-names>I</given-names></name>, <name><surname>Rujescu</surname><given-names>D</given-names></name>. <article-title>Association of a schizophrenia risk variant with memory function</article-title>. <source>Pharmacopsychiatry</source>. <year>2020</year>;<volume>53</volume>(<issue>02</issue>): <fpage>86</fpage>&#x02013;<lpage>87</lpage>.</mixed-citation></ref><ref id="pone.0270506.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Clark</surname><given-names>D</given-names></name>, <name><surname>Dedova</surname><given-names>I</given-names></name>, <name><surname>Cordwell</surname><given-names>S</given-names></name>, <name><surname>Matsumoto</surname><given-names>I</given-names></name>. <article-title>Altered proteins of the anterior cingulate cortex white matter proteome in schizophrenia</article-title>. <source>Proteomics Clin Appl</source>. <year>2007</year>;<volume>1</volume>(<issue>2</issue>): <fpage>157</fpage>&#x02013;<lpage>166</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/prca.200600541</pub-id>
<pub-id pub-id-type="pmid">21136665</pub-id></mixed-citation></ref><ref id="pone.0270506.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Kreilaus</surname><given-names>F</given-names></name>, <name><surname>Chesworth</surname><given-names>R</given-names></name>, <name><surname>Eapen</surname><given-names>V</given-names></name>, <name><surname>Clarke</surname><given-names>R</given-names></name>, <name><surname>Karl</surname><given-names>T</given-names></name>. <article-title>First behavioural assessment of a novel Immp2l knockdown mouse model with relevance for Gilles de la Tourette syndrome and Autism spectrum disorder</article-title>. <source>Behav Brain Res</source>. <year>2019</year>;<volume>374</volume>: <fpage>112057</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.bbr.2019.112057</pub-id>
<pub-id pub-id-type="pmid">31233820</pub-id></mixed-citation></ref><ref id="pone.0270506.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>George</surname><given-names>SK</given-names></name>, <name><surname>Jiao</surname><given-names>Y</given-names></name>, <name><surname>Bishop</surname><given-names>CE</given-names></name>, <name><surname>Lu</surname><given-names>B</given-names></name>. <article-title>Mitochondrial peptidase IMMP2L mutation causes early onset of age&#x02010;associated disorders and impairs adult stem cell self&#x02010;renewal</article-title>. <source>Aging Cell</source>. <year>2011</year>;<volume>10</volume>(<issue>4</issue>): <fpage>584</fpage>&#x02013;<lpage>594</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1474-9726.2011.00686.x</pub-id>
<pub-id pub-id-type="pmid">21332923</pub-id></mixed-citation></ref><ref id="pone.0270506.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>Y</given-names></name>, <name><surname>Mehta</surname><given-names>SL</given-names></name>, <name><surname>Lu</surname><given-names>B</given-names></name>, <name><surname>Li</surname><given-names>PA</given-names></name>. <article-title>Deficiency in the inner mitochondrial membrane peptidase 2-like (Immp21) gene increases ischemic brain damage and impairs mitochondrial function</article-title>. <source>Neurobiol Dis</source>. <year>2011</year>;<volume>44</volume>(<issue>3</issue>): <fpage>270</fpage>&#x02013;<lpage>276</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.nbd.2011.06.019</pub-id>
<pub-id pub-id-type="pmid">21824519</pub-id></mixed-citation></ref><ref id="pone.0270506.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>C</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Lu</surname><given-names>B</given-names></name>. <article-title>The Immp2l mutation causes age&#x02010;dependent degeneration of cerebellar granule neurons prevented by antioxidant treatment</article-title>. <source>Aging Cell</source>. <year>2016</year>;<volume>15</volume>(<issue>1</issue>): <fpage>167</fpage>&#x02013;<lpage>176</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/acel.12426</pub-id>
<pub-id pub-id-type="pmid">26616244</pub-id></mixed-citation></ref><ref id="pone.0270506.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>MT</given-names></name>, <name><surname>Beal</surname><given-names>MF</given-names></name>. <article-title>Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases</article-title>. <source>Nature</source>. <year>2006</year>;<volume>443</volume>(<issue>7113</issue>): <fpage>787</fpage>&#x02013;<lpage>795</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature05292</pub-id>
<pub-id pub-id-type="pmid">17051205</pub-id></mixed-citation></ref><ref id="pone.0270506.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Kumar</surname><given-names>RA</given-names></name>, <name><surname>Christian</surname><given-names>SL</given-names></name>. <article-title>Genetics of autism spectrum disorders</article-title>. <source>Curr Neurol Neurosci Rep</source>. <year>2009</year>;<volume>9</volume>(<issue>3</issue>): <fpage>188</fpage>&#x02013;<lpage>197</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11910-009-0029-2</pub-id>
<pub-id pub-id-type="pmid">19348707</pub-id></mixed-citation></ref><ref id="pone.0270506.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Ciaccio</surname><given-names>C</given-names></name>, <name><surname>Tucci</surname><given-names>A</given-names></name>, <name><surname>Scuvera</surname><given-names>G</given-names></name>, <name><surname>Estienne</surname><given-names>M</given-names></name>, <name><surname>Esposito</surname><given-names>S</given-names></name>, <name><surname>Milani</surname><given-names>D</given-names></name>. <article-title>16p13 microduplication without CREBBP involvement: Moving toward a phenotype delineation</article-title>. <source>Eur J Med Genet</source>. <year>2017</year>;<volume>60</volume>(<issue>3</issue>): <fpage>159</fpage>&#x02013;<lpage>162</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ejmg.2016.12.006</pub-id>
<pub-id pub-id-type="pmid">28007608</pub-id></mixed-citation></ref><ref id="pone.0270506.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Timms</surname><given-names>RT</given-names></name>, <name><surname>Menzies</surname><given-names>SA</given-names></name>, <name><surname>Tchasovnikarova</surname><given-names>IA</given-names></name>, <name><surname>Christensen</surname><given-names>LC</given-names></name>, <name><surname>Williamson</surname><given-names>JC</given-names></name>, <name><surname>Antrobus</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Genetic dissection of mammalian ERAD through comparative haploid and CRISPR forward genetic screens</article-title>. <source>Nat Commun</source>. <year>2016</year>;<volume>7</volume>(<issue>1</issue>): <fpage>1</fpage>&#x02013;<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ncomms11786</pub-id>
<pub-id pub-id-type="pmid">27283361</pub-id></mixed-citation></ref><ref id="pone.0270506.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Liang</surname><given-names>J</given-names></name>, <name><surname>Song</surname><given-names>W</given-names></name>, <name><surname>Tromp</surname><given-names>G</given-names></name>, <name><surname>Kolattukudy</surname><given-names>PE</given-names></name>, <name><surname>Fu</surname><given-names>M</given-names></name>. <article-title>Genome-wide survey and expression profiling of CCCH-zinc finger family reveals a functional module in macrophage activation</article-title>. <source>PloS One</source>. <year>2008</year>;<volume>3</volume>(<issue>8</issue>): <fpage>e2880</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0002880</pub-id>
<pub-id pub-id-type="pmid">18682727</pub-id></mixed-citation></ref><ref id="pone.0270506.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Fu</surname><given-names>M</given-names></name>, <name><surname>Blackshear</surname><given-names>PJ</given-names></name>. <article-title>RNA-binding proteins in immune regulation: a focus on CCCH zinc finger proteins</article-title>. <source>Nat Rev Immunol</source>. <year>2017</year>;<volume>17</volume>(<issue>2</issue>): <fpage>130</fpage>&#x02013;<lpage>143</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nri.2016.129</pub-id>
<pub-id pub-id-type="pmid">27990022</pub-id></mixed-citation></ref></ref-list></back></article>